C4 Therapeutics FY2022 net loss $128.2M; cash runway to end 2024

C4 Therapeutics, Inc.

2022-FY EPS reported -$2.62 revenue$31,096,000

Revenue $31.1M in FY2022, down from $45.8M in FY2021 due to Roche agreement termination.
Net loss $128.2M ($2.62/share) vs. $83.9M ($1.82/share) in FY2021; R&D spend rose to $117.8M.
Cash, equivalents and marketable securities $337.1M at Dec 31, 2022, down from $451.5M.
Phase 1 dose escalation data for CFT7455 (MM) and CFT8634 (synovial sarcoma) expected 2H 2023.
IND submission for CFT8919 (EGFR L858R) on track for 1H 2023; CFT1946 trial dosing patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

C4 Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $31.1 million, net income $128.2 million, EPS $2.62.

Period: the year ended December 31, 2022
Revenue: $31.1 million
Net income: $128.2 million
EPS: $2.62
Result: reported results

Exact text from the filing

Revenue: Total revenue for the year ended December 31, 2022 was $31.1 million, compared to $45.8 million for the year ended December 31, 2021.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-004835

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.